NEW DELHI: A pain medication developed by Glenmark PharmaceuticalsNSE 0.41 % has been dragged into controversy following allegations that several persons were deceived into participating in an ongoing clinical trial for the drug at a hospital in Rajasthan. The issue has escalated to a point where even the Central Drugs Standard Control Organisation, India's apex drug regulatory body, has sent inspectors to probe the matter, ET has learnt.